Table 1. Characteristics of the total study population, of patients who developed venous thromboembolism (VTE) and of patients who died during the observation period, as recorded at the time of entry into the study.
| All study patients n = 1840 | VTE during follow-upa n = 131 (7.1%) | Death during follow-upa n = 702 (38.2%) | ||
| Median Age, y (IQR) | 62 (52–68) | 61 (51–67) | 63 (55–70) | |
| Sex, n | ||||
| Female | 843 | 55 (6.5%) | 284 (33.7%) | |
| Male | 997 | 76 (7.6%) | 418 (41.9%) | |
| Site of cancer, n | ||||
| Lung | 309 | 21 (6.8%) | 194 (62.8%) | |
| Breast | 273 | 7 (2.6%) | 45 (16.5%) | |
| Lymphoma | 260 | 12 (4.6%) | 40 (15.4%) | |
| Brain | 245 | 32 (13.1%) | 131 (53.5%) | |
| Colon/Rectum | 182 | 14 (7.7%) | 63 (34.6%) | |
| Prostate | 157 | 3 (1.9%) | 31 (19.7%) | |
| Pancreas | 130 | 19 (14.6%) | 84 (64.6%) | |
| Stomach | 63 | 8 (12.7%) | 45 (71.4%) | |
| Kidney | 42 | 1 (2.4%) | 10 (23.8%) | |
| Multiple myeloma | 49 | 3 (6.1%) | 6 (12.2%) | |
| Others | 130 | 11 (8.5%) | 53 (40.8%) | |
| Newly diagnosed vs. recurrent disease, n | ||||
| Newly diagnosed | 1353 | 89 (8%) | 486 (35.9%) | |
| Recurrent disease | 487 | 25 (5.9%) | 216 (44.4%) | |
| Tumor group, n | ||||
| Localized solid tumor | 715 | 40 (5.6%) | 153 (21.4%) | |
| Solid tumors with distant metastasis | 571 | 44 (7.7%) | 372 (65.1%) | |
| Not classifiableb | 554 | 47 (8.5%) | 177 (31.9%) | |
| Median RDW, % (IQR) | 13.8 (13.1–14.6) | 14 (13.1–14.8) | 14.1 (13.3–15.0) | |
| RDW>16%, n | 188 | 17 (9%) | 102 (54.3%) | |
| RDW ≤16%, n | 1652 | 114 (6.5%) | 600 (36.3%) | |
| Median erythocyte count, T/l (IQR) | 4.40 (4.00–4.70) | 4.4 (4.1–4.7) | 4.3 (3.9–4.6) | |
| Median hematocrit, % (IQR) | 38.9 (35.5–41.5) | 39 (35.3–41.7) | 37.9 (34.2–40.8) | |
| Median hemoglobin concentration, g/dl (IQR) | 12.8 (11.8–14.1) | 13.1 (11.5–14.1) | 12.7 (11.4–13.8) | |
| Median MCV, fl (IQR) | 88.6 (85.4–91.7) | 87.7 (85.4–90.7) | 88.4 (85.0–91.7) | |
| Median MCH, pg (IQR) | 29.9 (28.6–31.0) | 29.9 (28.6–30.8) | 29.9 (28.3–31.0) | |
| Median MCHC, g/dl (IQR) | 33.7 (32.9–34.4) | 33.7 (33.1–34.5) | 33.7 (32.8–34.3) | |
| Use of ESA, nc | 54 | 9 (16.7%) | 38 (70.4%) |
a
Percentages are related to numbers given in the first column of the same line.
b
Brain tumor, lymphoma and multiple myeloma.
c
During the time period of one month before until 3 months after entry into the study.
Abbreviations: IQR = interquartile range (i.e. 25th–75th percentile), RDW = red cell distribution width, MCV = mean corpuscular volume, MCH = mean corpuscular hemoglobin, MCHC = mean corpuscular hemoglobin concentration, ESA = erythropoiesis-stimulting agent.